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Abstract
Previous studies including ours have demonstrated a critical function of the transcription factor ETV2 (ets variant 2;
also known as ER71) in determining the fate of cardiovascular lineage development. However, the underlying
mechanisms of ETV2 function remain largely unknown. In this study, we demonstrated the novel function of the
miR (micro RNA)-126-MAPK (mitogen-activated protein kinase) pathway in ETV2-mediated FLK1 (fetal liver kinase 1;
also known as VEGFR2)+ cell generation from the mouse embryonic stem cells (mESCs). By performing a series of
experiments including miRNA sequencing and ChIP (chromatin immunoprecipitation)-PCR, we found that miR-126
is directly induced by ETV2. Further, we identified that miR-126 can positively regulate the generation of FLK1+ cells
by activating the MAPK pathway through targeting SPRED1 (sprouty-related EVH1 domain containing 1). Further,
we showed evidence that JUN/FOS activate the enhancer region of FLK1 through AP1 (activator protein 1) binding
sequences. Our findings provide insight into the novel molecular mechanisms of ETV2 function in regulating
cardiovascular lineage development from mESCs.
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Introduction
The ETS (E26 transformation-specific or E-twenty-six
specific sequence) transcription factor family members
play key roles in diverse biological events including cell
survival, cancer, vascular-angiogenesis and hematopoiesis
mainly through the interaction between their conserved
ETS DNA binding domain and the consensus sequence
(5′-GGAA/T-3′) present in the regulatory elements of
their target genes [1, 2]. ETV2 (ets variant 2; also known
as ER71), a member of the ETS transcription factor family,
has been reported as an indispensable factor in establish-
ing the cardiovascular system [3, 4]. We previously dem-
onstrated that deficiency in Etv2 led to embryonic lethality
due to a complete lack of both vascular and hematopoietic
compartments [5, 6]. We also showed that ETV2 can dir-
ectly bind the promoters/enhancers of endothelial and
hematopoietic genes including Flk1 (fetal liver kinase 1;
also known as VEGFR2) [5–7]. Together with the findings
that ETV2 can induce de novo generation of FLK1+ cells,
the multipotent progenitor for blood, endothelial and car-
diac lineages from mouse embryonic stem cells (mESCs)
[5], these results strongly suggest the critical function of
ETV2 for the establishment of the cardiovascular system.
Reports from other groups further support the importance
of ETV2 in this process [8–11]. Regarding the regulatory
mechanisms of ETV2 functions, several studies examining
the ETV2 binding proteins have been reported. For ex-
ample, it was shown that the interaction between ETV2
and FOXC2 (forkhead box protein C2) plays an important
role in regulating several key genes of the endothelial and
hematopoietic lineages [12, 13]. Also, our recent study re-
vealed the functional significance of the ETV2-OVOL2
(ovo-like zinc finger 2) interaction in generating FLK1+
cells and its further differentiation into the hematopoietic
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and endothelial cells [14]. However, the detailed molecular
insight into the ETV2 function remains largely unknown.
To better understand the machinery of ETV2 that
regulates the FLK1+ cell generation from mESCs, we
profiled miRNAs (micro RNAs) that are differentially
regulated by ETV2 and found miR-126 as one of the
direct downstream players of ETV2. We subsequently
investigated the molecular mechanism of the miR-126/
MAPK (mitogen-activated protein kinase) pathway in
ETV2-mediated FLK1+ cell generation.
Materials and methods
Complete materials and methods are presented in
Additional file 1: Supplemental materials and methods.
Results
Analysis of ETV2-mediated miRNAs
To gain a novel insight into the molecular mechanisms of
ETV2 function in FLK1+ cell generation, we performed
miRNA profiling analysis. FLK1+ cells from doxycycline
(Dox)-inducible ETV2 in mESC (herein, iFLAG-ETV2
ESCs) [14] at day 3.5 of differentiation ±Dox were FACS
(fluorescence-activated cell sorting)-sorted and subjected to
miRNA sequencing (Fig. 1a). The miRNAs with ≥ 1.5 fold
change and a false discovery rate (FDR) ≤ 0.05 were consid-
ered to be significantly differentially expressed, resulting in
a total of 67 miRNAs of interest that were subsequently
subjected to unsupervised hierarchical clustering (Fig. 1b,
c). GO (gene ontology) term analysis indicated that the
ETV2-mediated miRNAs could be involved in diverse bio-
logical events with embryo development, cell differentiation
and anatomical structure development being top ranked
(Fig. 1d). Signaling pathways such as MAPK, RAP1 (ras-as-
sociated protein 1) and WNT (wingless-related integration
site) were identified as the major regulatory network of the
miRNAs, all of which are critical for cardiovascular devel-
opment (Additional file 2: Tables S1 and S2). Some of the
differentially expressed miRNAs were validated by qRT-
PCR (Fig. 1e and Additional file 3: Figure S1).
Among the differentially regulated miRNAs, miRNA-
126 drew our attention as an important player of ETV2-
mediated FLK1+ cell generation due to its function in
vascular development and hematopoiesis [15–17]. Inde-
pendently, our previous reports showed that Egfl7 (egf-
like domain multiple 7) [18], the host gene of miR-126,
is one of the most upregulated genes upon ETV2 over-
expression [6, 7]. Accordingly, we sought to determine
the functional consequence of miR-126 in regulating
ETV2-mediated FLK1+ cell generation.
ETV2 directly activates the expression of miR-126 through
Egfl7 promoter
First, we found a significant increment of the expression
of both miR-126 and Egfl7 in differentiating iFLAG-
ETV2 ESCs upon Dox treatment (Figs. 1e and 2a). Next,
we examined whether ETV2 can directly activate the
promoter of Egfl7, thus inducing the expression of miR-
126. From the literature search and our own investiga-
tion, we found the highly conserved upstream region of
the transcription start site in mouse and human EGFL7
that contains two conserved potential ETS binding sites
(Fig. 2b). By performing the promoter assay, we revealed
that the overexpression of Etv2 significantly increased
the activity of the Egfl7 promoter. However, the Egfl7
promoter construct with mutations on one putative ETS
site failed to respond to ETV2 (Fig. 2c). The results were
further corroborated by chromatin immunoprecipitation
(ChIP)-PCR assay, confirming in vivo occupancy of
ETV2 in Egfl7 promoter (Fig. 2d). Taken together, we
conclude that the expression of Egfl7 and thus miR-126
is directly regulated by ETV2 in differentiating mESCs.
The miR-126/MAPK pathway plays an important role for
ETV2-induced FLK1+ cell generation
MiR-126 (especially, miR-126-3p) can regulate the
MAPK pathway through the suppression of the SPRED1
expression, a negative regulator of the MAPK pathway
[15, 19]. Together with the report that treatment of
bFGF (basic fibroblast growth factor), an agonist of FGF
receptor-mediated signaling including MAPK [20], in-
creases the generation of the FLK1+ cells from mESCs
[21], we hypothesized that ETV2 induces FLK1+ cells
partly through the miR-126-MAPK pathway by sup-
pressing the expression of SPRED1. As shown in Fig. 3a
and b, while SPRED1 (sprouty related EVH1 domain
containing 1) was significantly reduced in response to
ETV2, augmented phospho-ERK1/2 (extracellular signal-
regulated kinases 1/2) level was evident upon the ETV2
overexpression in differentiating mESCs. Interestingly,
Etv2−/− ESCs showed an increased level of SPRED1 ex-
pression with concomitant decrease of phosphorylated
ERK1/2. Further, we found that ETV2-induced FLK1+
cell generation was significantly reduced in the presence
of U0126, a MAPK inhibitor, compared to the control
(Fig. 3c). To corroborate the findings, we transfected
Dox-inducible MAP2K1-8E, a catalytically inactive form
of MAP2K1 [22] into iFLAG-ETV2 mESCs in which
both ETV2 and MAP2K1-8E are co-overexpressed upon
Dox treatment. In agreement with the inhibitor treat-
ment (Fig. 3c), the co-expression of MAPK2K1-8E and
ETV2 led to a decreased generation of FLK1+ cells, com-
pared to the group in which ETV2 only is overexpressed
(Fig. 3d). Additionally, we went on to show that overex-
pression of SPRED1 was able to inhibit generation of
FLK1+ cells upon the overexpression of ETV2 (Fig. 3d).
These results clearly suggest that the SPRED1/MAPK
pathway plays an important role for ETV2-induced
FLK1+ cell generation from mESCs.
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Direct activation of FLK1 gene expression by the MAPK
pathway
To get a detailed insight into how the MAPK pathway
activated by ETV2 regulates the generation of FLK1+
cells, we examined the regulatory elements such as pro-
moter and enhancer of Flk1 gene [23] and found several
potential activator protein 1 (AP1) binding sequences in
Flk1 enhancer which is critical for controlling the en-
dogenous expression of Flk1 (Fig. 4a). AP1 (activator
protein 1), a heterodimeric transcriptional complex con-
sisting of JUN and FOS proteins, conveys the important
functions for multiple biological processes such as differ-
entiation, proliferation and apoptosis [24]. Given the
findings that AP1 complex acts as a downstream target
of the MAPK pathway [25], these suggest an important
mechanistic link between ETV2 and FLK1 gene ex-
pression via the MAPK-AP1 pathway. Therefore, we
first performed a luciferase-based promoter assay and
revealed that the activity of the Flk1-promoter/enhan-
cer (p/e) was increased in response to ETV2 or c-
JUN/FOS, a downstream of the MAPK pathway
(Fig. 4b, c). In contrast, both MKAP2K1-8E and the
JUN dominant negative mutant, c-JUN DN [26],
inhibited ETV2 function in activating Flk1-p/e
(Fig. 4b). Further, we showed that mutations on the
putative AP-1 binding site in the Flk1-p/e led to a
significantly reduced luciferase activity induced by c-
JUN/FOS (Fig. 4c). Collectively, these results suggest
that the MAPK pathway can activate the expression
of Flk1 gene partly through c-JUN/FOS.
Fig. 1 Analysis of ETV2-regualted miRNA expression in FLK1+ cells. a Schematic diagram of miRNA sequencing experiment. Doxycycline-inducible
(iFLAG-ETV2) mESCs were differentiated, treated with ± Doxycycline (Dox) at day 1 and sorted for FLK1+ cells at day 3.5. RNAs from the sorted
cells were subjected to miRNA sequencing and analysis. b Volcano plot showing the log2 fold change between +Dox versus −Dox against the
−log10 FDR-adjusted p value for each miRNA. miRNAs (FDR ≤ 0.05) with fold change of ≥ 1.5 (in red; upregulated) and ≤ − 1.5 (in green;
downregulated) were highlighted and selected. c Heatmap of the selected miRNAs in response to overexpression of ETV2. miRNAs upregulated
and downregulated in +DOX were indicated with gray and black bars, respectively. d Gene Ontology (GO) categories of selected miRNAs by
DIANA miRpath analysis. Bars indicate the significance level of miRNA target genes and interactions. e Differentiated iFLAG-ETV2 mESCs at day 3.5
were subjected to qRT-PCR analysis. n = 3, ***p < 0.001
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Discussion
In our study, several layers of novel findings on ETV2
function were made. First, we reported genome-wide
miRNA profiles in FLK1+ cells generated in response to
ETV2, providing a new research resource. Second, we
demonstrated the functional significance of the miR-
126/MAPK pathway in ETV2-mediated FLK1+ cell gen-
eration. Third, we also showed a direct activation of Flk1
enhancer by the JUN/FOS complex. Overall, our results
reveal that the miR-126/MAPK pathway constitutes a
novel mechanism responsible for ETV2-mediated Flk1
expression (Fig. 4d).
Our miRNA profiling results suggest that ETV2 regu-
lates development of FLK1+ cells, hematopoietic and
endothelial cell lineages as well as cardiomyocytes
through miRNAs. For example, miR-10b, one of the
downregulated miRNAs by ETV2, is a critical regulator
for vessel development through targeting FLT-1 (fms-re-
lated tyrosine kinase 1), which can inhibit VEGF (vascu-
lar endothelial growth factor)-FLK1 signaling [27]. In
contrast, miR-146a was upregulated in response to
ETV2 expression. Interestingly, miR-146 can target
CXCR4 (C-X-C chemokine receptor type 4), a receptor
of SDF1 (stromal cell-derived factor 1), whose signaling
is important during heart development and promotes
cardiogenesis from pluripotent stem cells [28–31]. An-
other downregulated miRNA by ETV2, miR-106, has
been reported as a critical player for cardiac develop-
ment as evidenced by in utero lethality displaying severe
cardiac defects in compound knockout of mouse miR-
106~25 and miR-17~92 cluster [32]. Thus, determining
biological consequences of the links between ETV2 and
ETV2-dependent miRNAs for cardiovascular lineage de-
velopment would be an interesting topic for further
studies.
Studies have shown that miR-126 plays important
functions in cardiovascular development and angiogen-
esis [15–17]. In this study, we provided evidence of the
unknown function of miR-126 in generating the first
emerging FLK1+ cells. Our results showed that ETV2 via
a direct binding on the Egfl7 promoter can induce the
expression of miR-126. In the subsequent studies, inhib-
ition of the miR-126/MAPK pathway leads to impair-
ment of ETV2-mediated FLK1+ cell generation. Thus,
Fig. 2 ETV2 upregulates miR126 expression through direct binding on Egfl7 promoter. a Expression analysis. iFLAG-ETV2 mESCs were
differentiated for 3.5 days ± Dox treatment and were subjected to gene expression analysis. n = 3, *p < 0.05. b Schematic diagram of Egfl7
promoter-luciferase plasmid. Two potential ETS binding elements were marked as diamonds, and their mutant sequences were shown in the
bottom. c HEK/293T cells were transiently co-transfected with pCMV-Etv2 and pGL3-luciferase constructs carrying wild type (Wt), or mutants of
Egfl7 promoter. Firefly luciferase activity was normalized by Renilla luciferase activity. n = 3. ***p < 0.001. d iFLAG-ETV2 mESCs were differentiated
in the presence of Dox for 3.5 days and then subjected to ChIP-PCR assay. Rabbit anti-FLAG or IgG antibody was used for the
immunoprecipitation. n = 3, **p < 0.01
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Fig. 3 (See legend on next page.)
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Fig. 3 ETV2 increases FLK1+ cells through the miR-126/MAPK pathway. A, B iFLAG-ETV2 mESCs were differentiated with ± Dox for 3.5 days and
subjected to western blot analysis for SPRED1 (A) and phosphorylated ERK1/2 (B). β-ACTIN and ERK1/2 were used as loading controls. (A’, B’) The
relative protein expression of SPRED1 and p-ERK1/2 was normalized against β-ACTIN and total ERK1/2, respectively. Differentiated Etv2−/− mESCs
were also included for the analysis. n = 3, *p < 0.05, **p < 0.01. (C) iFLAG-ETV2 mESCs were differentiated for 4 days in serum-free (upper) or for
3.5 days in serum (lower) conditions in the presence or absence of Dox. The resulting cells were analyzed for FLK1 expression by flow cytometry.
U0126 (5 μM) or U0124 (5 μM) was treated during the differentiation. C’ Quantification. n = 3, *p < 0.05. D Differentiated iFLAG-ETV2, iFLAG-ETV2-
MAP2K1-8E (iFLAG-ETV2-M) or iFLAG-ETV2-SPRED1 (iFLAG-ETV2-S) mESC ± Dox were analyzed for FLK1 expression by flow cytometry. D’
Quantification. n = 3, *p < 0.05
Fig. 4 ETV2 activates FLK1 expression through AP-1 binding sites in Flk1 enhancer region. a Schematic diagram of Flk1-promoter-enhancer (p/e)-
luciferase plasmid. Three potential AP-1 binding elements were marked as diamonds. b, c Luciferase-based promoter assay. b pGL3-Flk1 p/e was
transiently co-transfected with pCMV-Etv2, pMCL-MAP2K1-8E, pCMV-c-Jun ND (dominant negative form of c-Jun) into HEK/293T cells. n = 3, **p <
0.01, ***p < 0.001. c pGL3-luciferase construct carrying wild type (Wt), putative AP-1 binding site mutants (Mt #1, Mt #2, Mt #3) or enhancer
deletion mutant (del) of Flk1 p/e was co-transfected with pCMV-c-Jun and c-Fos into HEK/293T cells. Firefly luciferase activity was normalized by
Renilla luciferase activity. n = 3, ***p < 0.001. d A working model for ETV2-miR126/MAPK in regulating FLK1 expression. In addition to the direct
binding of ETV2 on the ETS binding sites in FLK1 gene, ETV2 activates miR-126, which can target SPRED1, thereby activating the MAPK pathway.
JUN/FOS, a downstream signaling complex of the MAPK pathway, subsequently activates gene transcription of FLK1 via the AP1 binding sites
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our results suggest a novel post-transcriptional regula-
tory mechanism of ETV2 in generating FLK1+ cell. Al-
though EGFL7 is co-transcribed with miR-126 upon
ETV2 expression, we rule out the potential contribution
of EGFL7 to inducing FLK1+ cell generation due to the
dispensable function of EGFL7 in early stages of em-
bryogenesis and embryonic vasculature formation as
demonstrated by knockout studies in mice and knock-
down experiments in differentiating ESCs [18, 33].
Taken together, it is evident that miR-126 acting down-
stream of ETV2 plays important roles in the establish-
ment of the cardiovascular system.
The molecular insights into Flk1 gene expression (i.e.,
determining its upstream regulators) has not been an ac-
tive research area, despite its critical function in
hematopoietic and vascular system. Regarding this, we
have demonstrated that ETV2 directly binds ETS bind-
ing elements present on both promoter and enhancer of
Flk1 and activates its expression [5]. The subsequent
ChIP sequencing analysis demonstrated that a wide
range of genes critical for endothelial cell and blood cells
are direct downstream targets of ETV2 [7]. In this
current study, we revealed an important function of
MAPK activity in regulating Flk1 gene expression. Over-
expression of ETV2 activates the MAPK activity, while
inhibition of the MAPK pathway decreases ETV2-
mediated FLK1+ cell generation. Further, we showed
that the MAPK pathway is able to directly upregulate
the expression of Flk1 via a direct binding of JUN/FOS
on Flk1 enhancer. Thus, we envision that ETV2 induces
Flk1 gene expression in a bimodal manner, one by acti-
vating the miR-126/MAPK pathway and the other by its
direct binding on Flk1 gene regulatory elements. In
mouse embryos, activated ERK1/2 is detected in the
blood islands, the first sites of blood and endothelial cell
development and later in the dorsal aorta and intersomi-
tic vessels [34]. Further, Erk2-deficient mouse embryos
are incompatible with proper mesoderm formation [35,
36]. Sprouty/Spred proteins, the negative effectors for
Ras/MAPK pathway [19], have inhibitory functions in
generating mesoderm and blood as well as vessel devel-
opment [37–40], further suggesting important functions
of the MAPK pathway in emergence of mesoderm with
hematopoietic and endothelial potential. Considering
that the enhanced protein stability of ETV2 by OVOL2
is thought to be one mechanism for ETV2-mediated
Flk1 gene transcription [14], it would be interesting to
see if the interaction between ETV2 and OVOL2 can
positively regulate the miR-126/MAPK pathway in this
process. In addition, the findings that ETV2 interacts
with OVOL2 [14] or FOXC2 [12] and that ETV2 and
JUN/FOS acts on Flk1 promoter and enhancer suggest a
hypothesis that ETV2 can form a transcriptional com-
plex with OVOL2, FOXC2, and/or AP1 to regulate the
expression of Flk1, which could provide an in-depth and
novel insight into molecular mechanisms behind the
ETV2-FLK1 axis.
In conclusion, we reported miRNA profiles regulated
by ETV2 in generating FLK1+ cells from mESCs. Fur-
ther, we showed that ETV2 can regulate the expression
of Flk1 through the miR126/MAPK pathway. These
findings could provide a novel insight into the mecha-
nisms of how ETV2 regulates the development of the
cardiovascular system. Studying the functions of other
miRNAs identified in this research would be important
for further deciphering the ETV2-miRNA regulatory
mechanisms in FLK1+ cell and cardiovascular lineage
generation. Since embryonic events can often play a crit-
ical role in adults, examination of our findings in patho-
physiological angiogenesis would be warranted.
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